Legend Biotech Corporation (NASDAQ:LEGN) saw a 5.5% spike in pre-market trading after reporting robust second-quarter results, with adjusted earnings of $0.16 per share and revenue of $387.5 million—both surpassing analyst expectations. The company attributed its performance largely to a 50% increase in CARVYKTI sales, now available in 348 sites across 19 markets, enhanced by significant growth in international sales. Additionally, Legend transitioned from an operating loss to a profit of $57.7 million, and reported positive clinical results for its investigational therapy LB2501. With a strong cash position of approximately $965 million, the firm is well-positioned to continue its growth trajectory and expand its CAR-T pipeline.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/healthcare/articles/legend-biotech-shares-rise-5-142521960.html
